Last €25.87 EUR
Change Today -0.01 / -0.04%
Volume 42.6K
As of 1:55 PM 07/24/14 All times are local (Market data is delayed by at least 15 minutes).

celesio ag (CLS1) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/7/14 - €26.35
52 Week Low
08/14/13 - €15.56
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CELESIO AG (CLS1)

Related News

No related news articles were found.

celesio ag (CLS1) Related Businessweek News

No Related Businessweek News Found

celesio ag (CLS1) Details

Celesio AG, a trading company, provides logistics and services to the pharmaceutical and healthcare sector in 14 countries worldwide. The company operates through two divisions, Consumer Solutions and Pharmacy Solutions. The Consumer Solutions division offers prescription and non-prescription pharmaceuticals; various medical services at its pharmacies; and pharmaceutical care and advice on medicines. This division serves through approximately 2,200 owned pharmacies and 4,300 participants in its brand partnership schemes. The Pharmacy Solutions division is engaged in the wholesale of pharmaceuticals; and property development for pharmacies. It provides oncological products and other medicines for the treatment of complex diseases; and offers supplementary services for pharmacists, such as the organization and management of pharmacy cooperation programs. This division operates approximately 130 wholesale branches that supply to approximately 65,000 pharmacies and hospitals. The company was founded in 1835 and is headquartered in Stuttgart, Germany. Celesio AG is a subsidiary of Franz Haniel & Cie. GmbH.

28,653 Employees
Last Reported Date: 03/18/14
Founded in 1835

celesio ag (CLS1) Top Compensated Officers

Chief Marketing Officer and Member of The Man...
Total Annual Compensation: €1.1M
Compensation as of Fiscal Year 2013.

celesio ag (CLS1) Key Developments

Celesio AG Announces Management Changes

The Supervisory Board of Celesio AG appointed Marc Owen as new members of the Management Board, with effect from July 16, 2014. Marc Owen will take over the position of Chairman of the Management Board and Alain Vachon will take over the position of Chief Financial Officer. The current speaker of the Management Board and Chief Financial Officer, Dr. Marion Helmes has by mutual agreement with the Supervisory Board resigned from her office and terminated her engagement with the company with effect as of the end of July 15, 2014. The Chief Operating Officer Martin Fisher has by mutual agreement with the Supervisory Board also resigned from his office with effect as of the end of May 22, 2014. Dr. Marion Helmes will additionally take over the position of interim Chief Operating Officer until and including July 15, 2014.

Celesio AG Announces Earnings Results for the First Quarter of 2014

Celesio AG announced earnings results for the first quarter of 2014. For the quarter, the company announced increased group revenue by 0.3% to EUR 5,379.5 million. After adjustments for negative currency effects, largely due to the Brazilian real, revenue increased by 2.1%. Following additional adjustments for the effects resulting from the changes in the consolidated group, in particular from the sale of the Irish wholesale business in May 2013, revenue actually increased significantly by 3.3%. Earnings before interest and taxes (EBIT) fell by 6.9% from EUR 95.1 million to EUR 88.6 million. After adjustments for special effects, EBIT was EUR 95.6 million and therefore 0.5% higher than the prior year's figure. Following further adjustments for currency effects, adjusted EBIT fell by 0.7%. The good performance in the United Kingdom made a significant contribution to offsetting the earnings situation, which continued to be weighed down by the persistently fierce discount war in the German wholesale business. Net profit was EUR 44 million or EUR 0.22 per share compared to EUR 41.7 million or EUR 0.23 per share a year ago. Net financial debt was EUR 1,614.5 million compared to EUR 934.2 million a year ago. EBITDA was EUR 118 million compared to EUR 126.6 million a year ago. Adjusted EBITDA was EUR 125 million compared to EUR 126.6 million a year ago. Adjusted EBIT was EUR 95.6 million compared to EUR 95.1 million a year ago. Negative free cash flow was EUR 186.7 million compared to EUR 82.2 million a year ago.

Celesio AG Reports Group Earnings Results for the Year 2013

Celesio AG reported group earnings results for the year 2013. For the year, the company reported revenue of EUR 21,407.7 million compared to EUR 22,270.8 million a year ago. EBITDA was EUR 532.8 million compared to EUR 542.5 million a year ago. Adjusted EBITDA was EUR 548.6 million compared to EUR 579.6 million a year ago. EBIT was EUR 406.6 million compared to EUR 370.1 million a year ago. Adjusted EBIT was EUR 423.6 million compared to EUR 444.8 million a year ago. Net profit was EUR 171.2 million compared to EUR 109.6 million a year ago. Adjusted net profit was EUR 186.4 million compared to EUR 201.5 million a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CLS1:GR €25.87 EUR -0.01

CLS1 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cardinal Health Inc $72.62 USD +1.17
Galenica AG SFr.879.00 CHF -5.00
McKesson Corp $192.99 USD +2.31
UDG Healthcare PLC 351.50 GBp -0.50
Walgreen Co $73.35 USD +0.45
View Industry Companies

Industry Analysis


Industry Average

Valuation CLS1 Industry Range
Price/Earnings 28.7x
Price/Sales 0.2x
Price/Book 1.8x
Price/Cash Flow 18.1x
TEV/Sales 0.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELESIO AG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at